Santen Pharmaceutical Co. - Price Target for Depositary Receipt (SNPHY) Reduced by 10.74% to 13.32

Written by Emily J. Thompson, Senior Investment Analyst

Source: NASDAQ.COM

Updated: Nov 09 2025

0mins

Source: NASDAQ.COM

Price Target Revision: The average one-year price target for Santen Pharmaceutical Co. has been revised down to $13.32 per share, a decrease of 10.74% from the previous estimate of $14.92, with current targets ranging from $10.90 to $17.34 per share.
Fund Sentiment: Three funds are reporting positions in Santen Pharmaceutical, with an average portfolio weight of 0.44%, which has increased by 9.43%. Institutional ownership has risen significantly by 160.01% over the last three months.
Shareholder Activity: Advisors Capital International Fund increased its holdings from 13K to 32K shares, a rise of 60.75%, while Rhumbline Advisers grew its position from 0K to 1K shares, marking a 97.49% increase. Copeland Capital Management reported no change in its holdings.
Fintel Overview: Fintel provides comprehensive investment research, including fundamentals, analyst reports, ownership data, and fund sentiment, aimed at individual investors and small hedge funds, with advanced quantitative models for stock picks.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.